bristol myers squibb news

AbbVie, Bristol Myers

AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie said that its Phase 2 trial investigating emraclidine as a once-daily oral monotherapy treatment for adults with schizophrenia did not meet the primary endpoint of showing a “statistically significant” improvement when compared with a placebo group.

Business Insider · 3d

Leerink sees AbbVie’s trial results as ‘clear positive’ for Bristol Myers

Leerink analyst David Risinger notes AbbVie (ABBV) announced on November 11 that emraclidine’s pivotal Phase 2 trials, EMPOWER-1 and

Stocktwits on MSN · 3d

Bristol-Myers Hits 14-Month High After AbbVie’s Schizophrenia Drug Fails, Boosting Retail Sentiment

Bristol Myers Squibb ($BMY) stock rocketed over 11% in early morning trading on Monday to hit a 14-month high of $61.08 after AbbVie's ($ABBV) experimental schizophrenia treatment failed in a pair of mid-stage studies.

2 Dividend Stocks to Buy Hand Over Fist

The Motley Fool on MSN · 19h

2 Beaten-Down Dividend Stocks to Buy and Hold

Here are two brilliant options along those lines: CVS Health ( CVS 0.44%) and Bristol Myers Squibb ( BMY -1.03%). Find out why, despite the issues they've faced, both of these healthcare dividend stocks are attractive to investors focused on the long game.

Yahoo · 9h

2 Dividend Stocks to Buy Hand Over Fist in November

The ability to get through challenging periods and continue performing well without resorting to dividend cuts. AbbVie has increased its payouts despite Humira's loss of patent exclusivity. The company is a Dividend King with an active streak of 52 consecutive payout increases.

Barchart on MSN · 6h

2 Energy Dividend Stocks to Buy This November for Growth and Income

As oil prices remain volatile around thelatest OPEC+ moves and ongoing demand concerns, all eyes are on the energy sector, especially as investors consider President-elect Trump’s energy policies. While deregulation could favor the energy sector,

Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

17h

Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week

Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...

BioSpace16h

Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment

Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...

MarketWatch2d

Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day

Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to ...

What's Going On With Bristol-Myers Squibb Shares Monday?

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

Buy, Sell, Or Hold BMY Stock?

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Wolfe starts Bristol Myers at Peer Perform, sees potential comeback story

Wolfe Research initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. The firm said there maybe a comeback story with Bristol, ...

7hon MSN

Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

Fintel on MSN2d

Leerink Partners Upgrades Bristol-Myers Squibb Company - Preferred Security (BMYMP)

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb Company - ...

Bristol Myers initiated with a Peer Perform at Wolfe Research

Wolfe Research analyst Alexandria Hammond initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. Published first on TheFly ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

AbbVie, Bristol Myers

2 Dividend Stocks to Buy Hand Over Fist

Related topics